> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT®)
> FHACT® cervical cancer detection test has potential application for more than 2 million patients per year in the United States
RUTHERFORD, N.J., Oct.
Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today
disclosed a development program for a P/neurokinin-1 (NK 1 )
receptor antagonist, which is used in the prevention of both acute- and
delayed-onset chemotherapy induced nausea and vomiting (CINV). NK 1
receptor antagonists are administered in combination with a 5-HT 3
receptor antagonist for the prevention of CINV.
Amkor Technology, Inc. (Nasdaq: AMKR), a leading provider of
semiconductor assembly and test services, today announced that it has
granted GLOBALFOUNDRIES a non-exclusive license to its proprietary
copper pillar wafer bump technology.
Sign-up for At the Association of Corporate Counsel (ACC) Annual Meeting 2014 UBIC Will Showcase its E-Discovery Suite Featuring Proprietary AI Based Data Analysis Platform Lit i View(R) investment picks
Agreement represents the first distributor relationship outside the mainland United States for the company's ophthalmic formulations, which are now available by prescription in 36 states and US territories
SAN DIEGO , Nov.
Dropless Therapy™ injectable and planned LessDrops™ topical compounded formulations offer the same patent-pending technology and the promise of significantly reducing or completely eliminating the number of patient eye drop administrations.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.